| Literature DB >> 35111140 |
Haiying Ma1, Yujuan Niu1.
Abstract
Highly pathogenic fowl adenovirus serotype 4 (FAdV-4) is the causative agent of hydropericardium syndrome (HPS), which is characterized by pericardial effusion and hepatitis, and is one of the foremost causes of economic losses to the poultry industry over the last 30 years. However, the metabolic changes in cells in response to FAdV-4 infection remain unclear. In order to understand the metabolic interactions between the host cell and virus, we utilized ultra-high-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry to analyze the metabolic profiles with hepatocellular carcinoma cell line (LMH) infected with FAdV-4. The results showed that FAdV-4 could restore metabolic networks in LMH cells and tricarboxylic acid cycle, glycolysis, and metabolism of purines, pyrimidines, alanine, aspartate, glutamate, and amino sugar and nucleotide sugar moieties. Moreover, FAdV-4 production was significantly reduced in LMH cells cultured in glucose or glutamine-deficient medium. These observations highlighted the importance of host cell metabolism in virus replication. Therefore, similarities and disparities in FAdV-4-regulation of the metabolism of host cells could help improve targeted drug and reduce infection.Entities:
Keywords: FAdV-4; LMH cells; UHPLC-QTOF-MS; glutamine metabolism; glycolysis; metabolomics
Year: 2022 PMID: 35111140 PMCID: PMC8801735 DOI: 10.3389/fmicb.2021.784745
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Characteristics of FAdV-4 infected LMH cells. (A) The replication characteristics of the virus in LMH cells were determined by qRT-PCR. 50% of the cells were infected with FAdV-4 at 24 hpi by indirect immunofluorescence (B), and viral inclusion bodies were observed in LMH cells (hematoxylin and eosin staining; × 400) (C).
FIGURE 2Score plots of PCA, PLS-DA and OPLS-DA of LMH cells infected with FAdV-4. PCA [(A) positive ion mode-ESI + ; (B) negative ion mode-ESI-], PLS-DA [(C) positive ion mode-ESI + ; (D) negative ion mode-ESI-], and OPLS-DA [(E) positive ion mode-ESI + ; (F) negative ion mode-ESI-] models were constructed using LC-MS/MS metabolomics data. Results indicate the separation of control and FAdV-4 group. The ellipses represent 95% confidence intervals of all samples.
FIGURE 3Analysis of the multiple of the difference of metabolite expression in positive ion mode (A) and negative ion mode (B). The X-axis indicates the differential expression multiple, red indicates that the differential expression multiple is greater than 1, and green indicates that the differential expression multiple is less than 1. The Y-axis indicates the significant difference metabolites.
Differential metabolites in FAdV-4-infected LMH cells compared to controls in positive ion mode.
| Name | VIP | FC (F vs. Ctrl) | KEGG ID | |
| Gly-Arg | 2.19 | 7.79E-07 | 1.67 | |
| Phe-met | 1.02 | 7.80E-07 | 1.71 | |
| Pro-arg | 1.69 | 3.49E-05 | 1.69 | |
| Asn-Lys | 1.44 | 4.11E-05 | 2.02 | |
| Methylphenidate | 1.19 | 6.48E-05 | 1.84 | C07196 |
| Thr-Leu | 1.07 | 6.63E-05 | 2.67 | |
| Leucylleucine | 1.34 | 7.61E-05 | 1.86 | C11332 |
| 2,4,6-tri-tert-butylaniline | 3.71 | 8.32E-05 | 1.49 | |
| His-Leu | 1.01 | 9.90E-05 | 1.85 | C05010 |
| Arg-asp | 1.13 | 1.48E-04 | 1.82 | |
| Pro-Ala | 1.03 | 1.73E-04 | 1.59 | |
| Leu-Thr | 1.17 | 2.20E-04 | 1.71 | |
| Leu-Phe | 1.94 | 2.79E-04 | 1.77 | |
| Arg-Ser | 2.01 | 3.30E-04 | 1.88 | |
| .gamma.-l-glu-.epsilon.-l-lys | 1.45 | 3.78E-04 | 2.33 | C21730 |
| Lys-Pro | 1.36 | 3.93E-04 | 1.71 | |
| Glu-Arg | 1.68 | 4.69E-04 | 1.72 | |
| Ureidoglutaric acid | 1.95 | 4.90E-04 | 1.43 | |
| Choline | 1.33 | 5.09E-04 | 2.39 | C00114 |
| Adenosine 5′-monophosphate | 10.4 | 5.81E-04 | 2.31 | C00020 |
| Desmethylbosentan | 1.54 | 6.12E-04 | 1.86 | |
| 1-(1z-hexadecenyl)-sn-glycero-3-phosphocholine | 1.65 | 8.45E-04 | 1.81 | |
| Val-Ile | 1.21 | 9.01E-04 | 1.79 | |
| Val-Arg | 1.46 | 9.37E-04 | 1.74 | |
| 1-o-hexadecyl-2-deoxy-2-thio-s-acetyl-sn-glyceryl-3-phosphorylcholine | 13.5 | 9.84E-04 | 1.71 | |
| Nortriptyline | 1.03 | 1.01E-03 | 1.26 | C07274 |
| NAD+ | 2.20 | 1.02E-03 | 1.87 | C00003 |
| Sulfosuccinimidyl oleate | 7.85 | 1.08E-03 | 2.03 | |
| Fingolimod | 1.34 | 1.42E-03 | 1.66 | |
| Eschscholtzxanthin | 1.13 | 1.49E-03 | 1.38 | C08593 |
| Gly-Lys | 1.08 | 1.56E-03 | 1.92 | |
| Gamma-glu-glu | 7.01 | 1.65E-03 | 2.06 | |
| Niacinamide | 3.88 | 1.67E-03 | 1.62 | C00153 |
| Benzenepropanamide, n-(6-chloro-2-benzothiazolyl)-3,4-dimethoxy- | 2.48 | 1.74E-03 | 2.72 | |
| Phosphocholine | 8.26 | 1.75E-03 | 3.15 | C00588 |
| Heliotrine | 1.09 | 1.86E-03 | 1.53 | C10324 |
| Arg-Ala | 3.86 | 1.99E-03 | 1.94 | |
| Aspartic acid | 1.59 | 2.93E-03 | 1.64 | C00049 |
| Methysticin | 6.17 | 3.10E-03 | 1.52 | C09952 |
| 1.18 | 3.40E-03 | 2.09 | C00449 | |
| 1.50 | 3.44E-03 | 1.51 | ||
| Adenosine, cyclic 3′,5′-[hydrogen [p(s)]-phosphorothioate] | 1.31 | 3.68E-03 | 1.64 | |
| Ala-Lys | 1.85 | 4.18E-03 | 1.41 | |
| 4.64 | 4.22E-03 | 1.36 | C00064 | |
| Oleyloxyethylphosphorylcholine | 1.62 | 4.32E-03 | 1.63 | |
| Schaftoside | 5.81 | 4.46E-03 | 2.48 | C10181 |
| 5- | 1.63 | 4.60E-03 | 2.28 | C03740 |
| Lactose | 4.92 | 4.71E-03 | 1.27 | C00243 |
| Glu-Gly-Arg | 2.90 | 4.74E-03 | 1.64 | |
| Lys-Gln | 1.73 | 5.05E-03 | 2.05 | |
| 1.64 | 5.59E-03 | 0.40 | ||
| Guanosine 5′-diphospho-.alpha.-d-mannose | 1.91 | 5.69E-03 | 2.28 | C00096 |
| 1.34 | 6.45E-03 | 1.45 | C01924 | |
| Asiatic acid | 1.50 | 6.67E-03 | 1.28 | C08617 |
| Uracil | 1.18 | 7.46E-03 | 1.93 | C00106 |
| 1-aminocyclopropanecarboxylic acid | 1.21 | 7.53E-03 | 1.35 | C01234 |
| Dl-norleucine methyl ester | 1.05 | 8.40E-03 | 1.97 | |
| (-)-.alpha.-kainic acid | 1.76 | 9.11E-03 | 1.61 | C12819 |
| (1s,2r-d-erythro-2-n-myristoylamino)-1-phenyl-1-propanol | 1.14 | 9.42E-03 | 1.30 | |
| 3.29 | 1.05E-02 | 1.35 | C00025 | |
| Tetramisole | 1.65 | 1.08E-02 | 1.87 | |
| Gardenin b | 1.84 | 1.26E-02 | 0.78 | C15109 |
| Furmecyclox | 1.70 | 1.29E-02 | 1.49 | C18912 |
| 2-palmitoyl-rac-glycerol | 1.35 | 1.32E-02 | 0.66 | |
| 2-acetamido-2-deoxy-3-o-(.alpha.-l-fucopyranosyl)-d-glucopyranose | 1.39 | 1.35E-02 | 1.63 | |
| 2.70 | 1.38E-02 | 1.29 | C02237 | |
| Tetraethylene glycol | 1.15 | 1.43E-02 | 1.56 | |
| 6h-dibenzo[b,d]pyran, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-methoxy-6,6,9- trimethyl-, (6ar,10ar)- | 1.15 | 1.49E-02 | 0.39 | |
| Thioridazine | 1.61 | 1.52E-02 | 1.52 | |
| Ile-Arg | 1.83 | 1.53E-02 | 1.70 | |
| Vesamicol | 1.09 | 1.83E-02 | 1.82 | |
| Adenosine | 4.76 | 2.09E-02 | 1.56 | C00212 |
| Lys-Thr | 1.05 | 2.14E-02 | 2.03 | |
| Adenine | 2.54 | 2.58E-02 | 1.31 | C00147 |
| Halofantrine | 1.87 | 2.71E-02 | 1.33 | C07634 |
| Ophthalmate | 2.10 | 3.06E-02 | 1.63 | C21016 |
| 3.63 | 3.42E-02 | 1.19 | C00170 | |
| 3.48 | 4.22E-02 | 1.49 | ||
| Gln-arg | 1.05 | 4.37E-02 | 1.53 | |
| Kaempferitrin | 1.04 | 4.45E-02 | 1.65 | C16981 |
| Methyl (r)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylate | 1.33 | 4.46E-02 | 1.14 | |
| Arg-Asn | 1.01 | 4.47E-02 | 1.77 | |
| Dimethyl adipate | 1.74 | 4.74E-02 | 0.71 | C14570 |
Name is the name of the metabolite.
FC (fold changes) is the difference multiple.
KEGG ID is the KEGG number of the metabolite.
E-a represents 10^a in P-value.
Differential metabolites in FAdV-4-infected LMH cells compared to controls in negative ion mode.
| Name | VIP | FC (F vs. Ctrl) | KEGG ID | |
| Val-Ala | 1.03 | 1.01E-04 | 1.96 | |
| Adenosine 5′-phosphosulfate | 5.84 | 5.41E-04 | 2.04 | C00224 |
| Guanosine 5′-monophosphate | 2.03 | 1.20E-03 | 2.20 | C00144 |
| Deoxythymidine 5′-phosphate (dTMP) | 1.14 | 1.47E-03 | 1.54 | C00364 |
| .beta.-nicotinamide adenine dinucleotide (NAD) | 1.04 | 1.52E-03 | 1.58 | C00003 |
| Gamma-l-glutamyl-l-glutamic acid | 3.53 | 2.69E-03 | 1.84 | C05282 |
| .alpha.- | 2.92 | 2.78E-03 | 2.27 | |
| Uridine 5′-monophosphate | 7.41 | 3.03E-03 | 2.05 | C00105 |
| Cdp-ethanolamine | 1.63 | 4.19E-03 | 1.71 | C00570 |
| Cyclic adenosine diphosphate ribose | 2.07 | 4.53E-03 | 1.44 | C13050 |
| Thymidine 5′-triphosphate | 1.78 | 5.38E-03 | 2.00 | C00459 |
| Val-Asp | 1.29 | 6.41E-03 | 1.87 | |
| Heptadecanoic acid | 1.47 | 6.91E-03 | 0.59 | |
| Glutamine | 4.79 | 1.00E-02 | 1.40 | C00064 |
| Diadenosine tetraphosphate | 1.02 | 1.02E-02 | 1.66 | |
| Geranyl diphosphate | 1.67 | 1.05E-02 | 1.61 | C05847 |
| 6-phosphogluconic acid | 1.03 | 1.07E-02 | 1.91 | C00345 |
| Udp-n-acetylglucosamine | 12.1 | 1.14E-02 | 1.82 | C00043 |
| Dihydro-4,4-dimethyl-2,3-furandione | 2.30 | 1.54E-02 | 1.41 | C01125 |
| Gln-glu | 2.31 | 2.18E-02 | 1.80 | |
| Thymidine 5′-diphosphate | 2.13 | 2.23E-02 | 1.91 | C00363 |
| Pyruvate | 1.37 | 2.30E-02 | 0.65 | C00022 |
| alpha- | 3.09 | 2.46E-02 | 1.59 | C00103 |
| 1.18 | 2.66E-02 | 1.48 | ||
| 1-(1z-octadecenyl)-2-(4z,7z,10z,13z,16z,19z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine | 2.21 | 2.85E-02 | 0.69 | |
| 9.05 | 2.90E-02 | 1.20 | C02480 | |
| Zinniol | 2.73 | 2.99E-02 | 0.60 | C10840 |
| Glycine, n,n′-[1,2-ethanediylbis(oxy-2,1-phenylene)]bis[n-(carboxymethyl)- | 2.60 | 3.23E-02 | 1.68 | |
| sn-Glycerol 3-phosphoethanolamine | 3.80 | 3.44E-02 | 1.62 | |
| 3.19 | 3.51E-02 | 1.23 | C00402 | |
| Phenol,4-[2-[[2-benzo[b]thien-3-yl-9-(1-methylethyl)-9h-purin-6-yl]amino]ethyl]- | 1.25 | 3.58E-02 | 1.65 | |
| Glycerol 3-phosphate | 1.35 | 3.74E-02 | 1.30 | C00093 |
| Udp-galactose | 2.14 | 3.81E-02 | 1.50 | C00052 |
| Cytidine 5′-monophosphate | 1.25 | 3.92E-02 | 1.55 | C00055 |
| Rhamnetin | 2.63 | 4.18E-02 | 1.05 | C10176 |
| 3.53 | 4.48E-02 | 1.45 | C01879 | |
| Glutathione, oxidized | 9.09 | 4.76E-02 | 2.78 | C00127 |
| Glutamic acid | 4.00 | 4.99E-02 | 1.20 | C00025 |
Name is the name of the metabolite.
FC (fold changes) is the difference multiple.
KEGG ID is the KEGG number of the metabolite.
E-a represents 10^a in P-value.
FIGURE 4Heatmap of differentially expressed metabolites in LMH cells infected with FAdV-4. Each row in the figure represents a differential metabolite (the ordinate is the metabolite with significant differential expression), and each column represents a group of samples (the abscissa is the sample information). Red represents significant up regulation, blue represents significant down regulation, color depth indicates the degree of up regulation and down regulation, and metabolites with similar expression patterns gather in the same cluster on the left.
FIGURE 5Pearson’s of differentially expressed metabolites in positive ion mode (A) and negative ion mode (B). Red indicates positive correlation, blue indicates negative correlation, and white indicates no significant correlation. The color depth is related to the absolute value of correlation coefficient. The higher the degree of positive correlation or negative correlation, the darker the color. The size of the point is related to the significance of the correlation, the more significant.
Differential metabolites in FAdV-4-infected LMH cells compared to controls in negative ion mode.
| Metabolic pathway | |
| Pyrimidine metabolism | 0.00 |
| Neuroactive ligand-receptor interaction | 0.00 |
| Zeatin biosynthesis | 0.00 |
| Purine metabolism | 0.00 |
| Alanine, aspartate and glutamate metabolism | 0.00 |
| FoxO signaling pathway | 0.00 |
| ABC transporters | 0.00 |
| Taste transduction | 0.00 |
| Renin secretion | 0.00 |
| AMPK signaling pathway | 0.00 |
| cGMP-PKG signaling pathway | 0.00 |
| 0.00 | |
| Cysteine and methionine metabolism | 0.00 |
| Oxidative phosphorylation | 0.00 |
| Lysosome | 0.00 |
| Glutathione metabolism | 0.00 |
| Taurine and hypotaurine metabolism | 0.00 |
| Protein digestion and absorption | 0.00 |
| Arginine biosynthesis | 0.00 |
| Glycerophospholipid metabolism | 0.00 |
| Aminoacyl-tRNA biosynthesis | 0.00 |
| Metabolic pathways | 0.00 |
| Biosynthesis of amino acids | 0.00 |
| Nicotinate and nicotinamide metabolism | 0.00 |
| Olfactory transduction | 0.00 |
| Longevity regulating pathway | 0.00 |
| Glutamatergic synapse | 0.00 |
| GABAergic synapse | 0.00 |
| Pantothenate and CoA biosynthesis | 0.00 |
| Longevity regulating pathway—worm | 0.01 |
| beta-Alanine metabolism | 0.01 |
| Calcium signaling pathway | 0.01 |
| Photosynthesis | 0.01 |
| Insulin secretion | 0.01 |
| Synaptic vesicle cycle | 0.01 |
| Monobactam biosynthesis | 0.01 |
| Regulation of lipolysis in adipocytes | 0.01 |
| Platelet activation | 0.01 |
| Bacterial secretion system | 0.01 |
| HIF-1 signaling pathway | 0.01 |
| Galactose metabolism | 0.02 |
| Proximal tubule bicarbonate reclamation | 0.02 |
| Histidine metabolism | 0.02 |
| Glycine, serine and threonine metabolism | 0.02 |
| Nitrogen metabolism | 0.02 |
| Biosynthesis of various secondary metabolites—part 3 | 0.02 |
| Two-component system | 0.02 |
| Aldosterone synthesis and secretion | 0.03 |
| Carbon fixation in photosynthetic organisms | 0.03 |
| Thermogenesis | 0.03 |
| cAMP signaling pathway | 0.03 |
| Glyoxylate and dicarboxylate metabolism | 0.03 |
| Amino sugar and nucleotide sugar metabolism | 0.03 |
| Glucagon signaling pathway | 0.03 |
| Carbon metabolism | 0.04 |
| Ferroptosis | 0.04 |
| mTOR signaling pathway | 0.04 |
| PI3K-Akt signaling pathway | 0.04 |
| Thiamine metabolism | 0.05 |
| Glycolysis/Gluconeogenesis | 0.05 |
0.00 means that P-value is less than 0.01.
FIGURE 6KEGG enrichment pathway map. The vertical axis represents each KEGG metabolic pathway, and the horizontal axis represents the number of differentially expressed metabolites in each KEGG metabolic pathway. Color represents the P value of enrichment analysis. The darker the color is, the smaller the P value is, and the more significant the enrichment degree is. The number on the column represents the proportion of different metabolites in the detected metabolites.
FIGURE 7Schematic representation of altered metabolic pathways in LMH cells infected with FAdV-4.
FIGURE 8Western blot analysis hexon expression in LMH cells by affecting glucose and glutamine metabolism. The destination strip is marked in the red box, and the below bands are non-specific.